Click Therapeutics and Boehringer Ingelheim have announced a strategic financing and commercialization agreement centered on CT-155, an investigational prescription digital therapeutic for schizophrenia. The deal includes a $50 million Series D investment from Boehringer Ingelheim alongside additional funding to support commercialization activities.
As part of the agreement, Boehringer Ingelheim will transfer full product responsibility for CT-155 to Click Therapeutics, including commercial and marketing authorization rights, contingent on regulatory clearance. The companies previously co-developed the therapy, which targets experiential negative symptoms of schizophrenia as an adjunct to standard antipsychotic treatment.
“Boehringer Ingelheim’s selection of Click to deliver CT-155 to patients is powerful validation of our vision and the capabilities we have spent over a decade building,” said David Benshoof Klein, CEO and founder of Click Therapeutics. “We are eager to take the lead with CT-155 and are focused on getting this FDA-designated Breakthrough Device to patients after clearance by the FDA.”
The commercialization strategy is supported by results from the Phase III CONVOKE study, a randomized, double-blind, controlled trial evaluating CT-155 against a digital control app. The study met its primary endpoint, demonstrating a statistically significant reduction in experiential negative symptoms at 16 weeks.
Key findings include:
A Cohen’s D effect size of -0.36 (p value = 0.0003)
A 6.8-point improvement in CAINS-MAP scores versus 4.2 points in the control arm
A 62% relative improvement in symptom severity
CT-155 also demonstrated a favorable safety profile, with adverse event rates of 8.3% compared to 13.4% in the control group. No serious adverse events were reported in either arm, and no discontinuations were attributed to CT-155.
“Fostering science to create new treatments for patients is at the heart of what we do,” said Jan Stefan Scheld, Head of Global Therapeutic Areas at Boehringer Ingelheim. "The collaboration with Click Therapeutics has played a vital role in advancing a potentially meaningful innovation for people living with schizophrenia and we believe this agreement enables Click to continue on our successful co-development of CT-155, leveraging their capabilities and expertise to maximize its impact.”
CT-155 received FDA Breakthrough Device designation in 2024 and continues to be evaluated in additional studies, including the ENSPIRUS trial, which aims to generate further real-world evidence.
Click here for the original news story.